[go: up one dir, main page]

ATE516306T1 - Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen - Google Patents

Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen

Info

Publication number
ATE516306T1
ATE516306T1 AT04700825T AT04700825T ATE516306T1 AT E516306 T1 ATE516306 T1 AT E516306T1 AT 04700825 T AT04700825 T AT 04700825T AT 04700825 T AT04700825 T AT 04700825T AT E516306 T1 ATE516306 T1 AT E516306T1
Authority
AT
Austria
Prior art keywords
tfpi
chromatography
analog
sepharose
concentration
Prior art date
Application number
AT04700825T
Other languages
English (en)
Inventor
David H Reifsnyder
Duane Inlow
Glen Dorin
Patricio T Riquelme
Cynthia Cowgill
Doug G Bolesch
Mark E Gustafson
Original Assignee
Novartis Vaccines & Diagnostic
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic, Pharmacia & Upjohn Co Llc filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE516306T1 publication Critical patent/ATE516306T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
AT04700825T 2003-08-13 2004-01-08 Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen ATE516306T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49454603P 2003-08-13 2003-08-13
US50927703P 2003-10-08 2003-10-08
US51219903P 2003-10-20 2003-10-20
PCT/US2004/000234 WO2005019265A1 (en) 2003-08-13 2004-01-08 Improved method of purifying tfpi and tfpi analogs

Publications (1)

Publication Number Publication Date
ATE516306T1 true ATE516306T1 (de) 2011-07-15

Family

ID=34222354

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04700825T ATE516306T1 (de) 2003-08-13 2004-01-08 Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen

Country Status (6)

Country Link
US (1) US7851433B2 (de)
EP (1) EP1654283B1 (de)
JP (2) JP4522997B2 (de)
AT (1) ATE516306T1 (de)
CA (1) CA2535562A1 (de)
WO (1) WO2005019265A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2285632T3 (es) * 1995-06-07 2007-11-16 Novartis Vaccines And Diagnostics, Inc. Formulacion acuosa que comprende tfpi y agentes solubilizadores.
ATE516306T1 (de) * 2003-08-13 2011-07-15 Novartis Vaccines & Diagnostic Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen
BRPI0611049A2 (pt) * 2005-05-06 2010-08-10 Novartis Ag utilização de tfpi para tratar infecções bacterianas severas
EP1996697A2 (de) * 2006-03-07 2008-12-03 Novartis AG Verhinderung von norvalin- und norleucin-fehlinkorporation in rekombinante proteine
US8088599B2 (en) * 2009-02-06 2012-01-03 Fudan University Nucleic acids encoding genetically modified tissue factor pathway inhibitor (TFPI) and method of making the same
WO2011028962A1 (en) * 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody coformulations
AU2023281912A1 (en) 2022-06-03 2024-12-12 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3325223A1 (de) * 1983-07-13 1985-01-24 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
EP0325691B1 (de) * 1988-01-25 1993-04-07 Consortium für elektrochemische Industrie GmbH Verfahren zur Solubilisierung von unlöslichem Protein
DK0414374T3 (da) 1989-07-25 1998-03-09 Smithkline Beecham Biolog Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf
EP0473564B1 (de) 1990-08-27 1996-03-20 Monsanto Company Anticoagulatorische Zusammensetzung aus LACI und sulfatierten Polysacchariden
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
EP0967279B1 (de) 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Helicobacter pylori Cytotoxin verwendbar in Impfstoffe und Diagnostik
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
US5276015A (en) * 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
EP0643585B1 (de) 1992-06-01 1999-12-15 Chiron Corporation Zusammensetzungen enthaltend Lipoprotein-Associated-Coagulation-Inhibitor (LACI) zur Herstellung eines Medikaments zur Behandlung von akuten oder chronischen Enzündungen
US6063764A (en) 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
AU4408493A (en) 1992-06-11 1994-01-04 Washington University Prophylaxis and treatment of sepsis and sepsis-associated coagulation disorders
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
IL113497A (en) 1994-04-28 2001-01-11 Amgen Inc Method for controlling metallophosphate precipitation in high cell density fermentations
EP0769018B1 (de) 1994-07-01 2002-12-18 Chiron Corporation Helicobacter proteine und impstoffe
DE69530084T2 (de) 1994-07-07 2004-02-05 Washington University Methode zur verminderung arterieller stenose
US5824644A (en) * 1994-07-07 1998-10-20 G. D. Searle & Co. Method of attenuating arterial stenosis
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JP3779728B2 (ja) * 1994-08-05 2006-05-31 カイロン コーポレイション 組織因子活性インヒビターの産生
US6242414B1 (en) * 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5885781A (en) * 1995-06-07 1999-03-23 Chiron Corporation Regulation of cytokine synthesis and release
ES2285632T3 (es) * 1995-06-07 2007-11-16 Novartis Vaccines And Diagnostics, Inc. Formulacion acuosa que comprende tfpi y agentes solubilizadores.
JPH11507060A (ja) 1995-06-07 1999-06-22 カイロン コーポレイション サイトカイン合成および放出の調節
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
CN101293920B (zh) 1998-05-01 2012-07-18 诺华疫苗和诊断公司 脑膜炎奈瑟球菌抗原和组合物
DE60031999T2 (de) * 1999-10-04 2007-06-06 Novartis Vaccines and Diagnostics, Inc., Emeryville Stabilisierte flüssige polypeptid-haltige pharmazeutische zusammensetzungen
CN100339482C (zh) 2000-02-28 2007-09-26 启龙股份公司 奈瑟球菌蛋白质的杂交表达
CA2463655A1 (en) * 2001-10-15 2003-04-24 Chiron Corporation Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
ATE516306T1 (de) * 2003-08-13 2011-07-15 Novartis Vaccines & Diagnostic Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen

Also Published As

Publication number Publication date
US20050037475A1 (en) 2005-02-17
JP4522997B2 (ja) 2010-08-11
CA2535562A1 (en) 2005-03-03
WO2005019265A1 (en) 2005-03-03
JP2007528211A (ja) 2007-10-11
JP2010031055A (ja) 2010-02-12
EP1654283A1 (de) 2006-05-10
EP1654283B1 (de) 2011-07-13
US7851433B2 (en) 2010-12-14

Similar Documents

Publication Publication Date Title
NO20061026L (no) Nye insulinderivater
ATE549028T1 (de) Stabile analoga von glp-1
ATE408624T1 (de) Verfahren zur reinigung von fsh
ATE446313T1 (de) Muteine von tränen-lipocalin
DE60333963D1 (de) Zytokin Ligand zur Behandlung von Asthma und Atemwegsüberreaktivität
ATE361313T1 (de) Allgemeines verfahren zur rückfaltung rekombinanter proteine
ATE349460T1 (de) Rückfaltung von protein-aggregaten und einschlussteilchen durch hohen druck
EP0134479A1 (de) Modifizierte Protease-Inhibitoren, Verfahren zu ihrer Herstellung und daraus bereitete pharmazeutische Mittel
ATE516306T1 (de) Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen
ATE449104T1 (de) Verfahren zur reinigung von fibrinogen
DE3686954D1 (de) Loeslichkeits-, reinigungs- und charakterisierungsverfahren fuer proteine aus unloeslichen proteinaggregaten oder proteinkomplexen und diesbezuegliche praeparate.
DE60233722D1 (de) Insulinvorstufen und verfahren zu deren herstellung
DE170917T1 (de) Neues derivat des humangammainterferon-polypeptids.
ATE381945T1 (de) Verfahren zur solubilisierung von peptid- mischungen
WO2004026891A3 (en) Protein purification
DE502004003404D1 (de) Verfahren zur reinigung von dimethylacetamid (dmac)
ATE333469T1 (de) Verfahren zur reinigung hochanionischer proteine
DE602004004156D1 (de) Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4-rezeptor (mc4) als agonist wirkenden peptids
ATE404577T1 (de) Verfahren zur herstellung von eplerenon
ATE378309T1 (de) Verfahren zur reinigung und herstellung von fluorkohlenwasserstoffen
DE602004017448D1 (de) Verfahren zur tensid-quantifizierung eines proteinpräparates
ATE437178T1 (de) Analgetisches antitumorpeptid aus skorpionen und verfahren zu dessen herstellung
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
DE60318749D1 (de) Paralytisches peptide von der spitzmaus sowie dessen nutzung in der therapie von neuromuskulären krankheiten
ATE383369T1 (de) Neues peptid sy

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties